Publication Year: 2013
-
A Blood-Based Proteomic Classifier for the Molecular Characterization of Pulmonary Nodules
-
Tissue biomarker analysis in PROSE, a randomized proteomic stratified phase III study of second line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (NSCLC)
-
Extending the Information Content of the MALDI Analysis of Biological Fluids (Deep MALDI)
-
Serum Mass Spectrometry Analysis in Primary Ovarian Cancer (OC) Treated with Surgery and Adjuvant Chemotherapy (CT)
-
Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial.
-
Serum and Tumor Biomarkers Predict Outcome in the eLung Trial, a Multicenter, Randomized Phase IIb Study of Standard Platinum Doublets plus Cetuximab as First-line Treatment of Advanced Non-Small Cell Lung Cancer
-
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIB/IV Non–Small-Cell Lung Cancer
-
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation
-
The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer
-
Phase II Trial of Sorafenib (S) and Erlotinib (E) in Unresectable Pancreas Cancer (UPC): Final Results and Correlative Findings